These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27861316)

  • 1. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
    Boehr S; Haen E
    Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
    Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
    Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma.
    Zhang YF; Liu XQ; Wang Y; Xu X; Zhong MK; Zhang P; Ma CL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122952. PubMed ID: 34598085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
    Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
    Wiesen MHJ; Blaich C; Streichert T; Michels G; Müller C
    Clin Chem Lab Med; 2017 Aug; 55(9):1349-1359. PubMed ID: 28328524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
    Baldelli S; Cattaneo D; Pignatelli P; Perrone V; Pastori D; Radice S; Violi F; Clementi E
    Bioanalysis; 2016 Feb; 8(4):275-83. PubMed ID: 26808218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
    Lindahl S; Dyrkorn R; Spigset O; Hegstad S
    Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
    Pan EY; Sobieraj DM
    Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
    [No Abstract]   [Full Text] [Related]  

  • 11. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
    Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
    Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
    Zhao Y; Couchman L; Kipper K; Arya R; Patel JP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122095. PubMed ID: 32251991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
    Ašić A; Marjanović D; Mirat J; Primorac D
    Per Med; 2018 May; 15(3):209-221. PubMed ID: 29767545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
    Gouveia F; Bicker J; Santos J; Rocha M; Alves G; Falcão A; Fortuna A
    J Pharm Biomed Anal; 2020 Mar; 181():113109. PubMed ID: 31981828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice.
    Wright C; Brown R; Cuker A
    Int J Lab Hematol; 2017 May; 39 Suppl 1():31-36. PubMed ID: 28447413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
    Zhang M; Moore GA; Chin PKL
    Ther Drug Monit; 2020 Jun; 42(3):473-480. PubMed ID: 32053549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.